NZ626742A - Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer - Google Patents

Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Info

Publication number
NZ626742A
NZ626742A NZ626742A NZ62674213A NZ626742A NZ 626742 A NZ626742 A NZ 626742A NZ 626742 A NZ626742 A NZ 626742A NZ 62674213 A NZ62674213 A NZ 62674213A NZ 626742 A NZ626742 A NZ 626742A
Authority
NZ
New Zealand
Prior art keywords
inhibitor
egfr
clusterin
treat cancer
egfr inhibitor
Prior art date
Application number
NZ626742A
Other languages
English (en)
Inventor
Gilles Bernard Tremblay
Elisabeth Viau
Mario Filion
Original Assignee
Alethia Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics Inc filed Critical Alethia Biotherapeutics Inc
Publication of NZ626742A publication Critical patent/NZ626742A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ626742A 2012-02-22 2013-02-22 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer NZ626742A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601786P 2012-02-22 2012-02-22
PCT/CA2013/000167 WO2013123588A1 (en) 2012-02-22 2013-02-22 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Publications (1)

Publication Number Publication Date
NZ626742A true NZ626742A (en) 2016-06-24

Family

ID=49004878

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ626742A NZ626742A (en) 2012-02-22 2013-02-22 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Country Status (11)

Country Link
US (1) US9822170B2 (enExample)
EP (1) EP2817028A4 (enExample)
JP (1) JP2015512877A (enExample)
CN (1) CN104159611A (enExample)
AU (1) AU2013224591A1 (enExample)
BR (1) BR112014020756A2 (enExample)
CA (1) CA2862739A1 (enExample)
EA (1) EA201491568A1 (enExample)
MX (1) MX2014010164A (enExample)
NZ (1) NZ626742A (enExample)
WO (1) WO2013123588A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2504363T (pt) 2009-11-24 2019-08-02 Nat Res Council Canada Anticorpos anticlusterina e fragmentos de ligação ao antigénio e a sua utilização para reduzir o volume de um tumor
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
MX2016010177A (es) 2014-02-07 2017-01-09 Dong Wha Pharm Co Ltd Composicion adyuvante anticancerosa que contiene promotor de la expresion de rip3 como principio activo, metodo para la deteccion de adyuvante anticanceroso que potencia la sensibilidad al farmaco anticanceroso mediante la estimulacion de la expresion de rip3 y metodo para controlar la sensibilidad del farmaco anticanceroso.
WO2016098041A1 (en) 2014-12-18 2016-06-23 Saarum Sciences Private Ltd Establishment and use of an in vitro platform for emt
CN105988004B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1胶体金定量检测试纸卡
CN105987997B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1荧光定量检测试纸卡
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
WO2020154627A1 (en) * 2019-01-25 2020-07-30 Promab Biotechnologies, Inc. Epcam antibody and epcam-car-t cells
CN114249832B (zh) * 2020-09-24 2023-11-10 博源润生医药（杭州）有限公司 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
AU2021442702A1 (en) * 2021-04-27 2023-11-30 Alethia Biotherapeutics Ulc Method for allowing immune cells infiltration in tumors
CN117903305B (zh) * 2023-12-05 2024-08-27 南京欧凯生物科技有限公司 针对雌二醇的单克隆抗体、基于其的检测试剂及其应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3933850A1 (de) 1989-10-06 1991-04-18 Schering Ag Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6464975B2 (en) 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
KR100820266B1 (ko) 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
AU763954B2 (en) 1999-04-28 2003-08-07 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
AU2001245280A1 (en) 2000-03-07 2001-09-17 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001075177A2 (en) 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2004521627A (ja) 2001-02-09 2004-07-22 インサイト・ゲノミックス・インコーポレイテッド 細胞増殖、細胞分化および細胞死に関連するタンパク質
WO2003004646A2 (en) 2001-04-04 2003-01-16 Elan Corporation, Plc Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
US20030134301A1 (en) 2001-07-27 2003-07-17 Brooksbank Robert Alan Identification and use of molecules implicated in pain
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2469941A1 (en) 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP4491240B2 (ja) 2002-01-17 2010-06-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Ｉｇｆｂｐ−２およびｉｇｆｂｐ−５を阻害する二重特異性アンチセンスオリゴヌクレオチド、並びにこれらの使用方法
EP1487857A4 (en) 2002-03-07 2006-08-09 Ludwig Inst Cancer Res BLOOD AND LYMPHATIC ENDOTHELIAL CELL GENES
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
DK1530636T3 (da) 2002-08-21 2010-11-29 Univ British Columbia Behandling af melanomer ved reduktion af clusterinniveauet
NZ552872A (en) 2002-08-21 2007-11-30 Univ British Columbia RNAI probes targeting cancer-related proteins
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
US20050048490A1 (en) 2002-09-26 2005-03-03 Incyte Corp. Proteins associated with cell growth, differentiation, and death
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
EP1603514A4 (en) 2003-01-24 2007-08-22 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR THYROID CANCER AND APPLICATION METHOD
WO2005049806A2 (en) 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20070134260A1 (en) 2003-03-28 2007-06-14 Georg Feger Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
WO2004092378A2 (en) 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
JP2007523839A (ja) 2003-04-18 2007-08-23 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 血管新生性障害の治療法
WO2004111273A2 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005012875A2 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2538763C (en) 2003-09-11 2015-05-05 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
AT412785B (de) 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
EP1708961B1 (en) 2003-12-04 2011-03-09 Abbott Biotherapeutics Corp. Anti-ip-10 antibodies
GB0329254D0 (en) 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
AU2005206389A1 (en) 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
JP2007522157A (ja) * 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体の高濃縮液体製剤
ITRM20040098A1 (it) 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
JP2008506123A (ja) 2004-07-09 2008-02-28 トリパス イメージング， インコーポレイテッド 卵巣癌の検出のための方法および組成物
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
CA2582683A1 (en) 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian eag1 ion channel protein
DK1814595T3 (da) 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
AU2006207999A1 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
WO2006089586A1 (en) 2005-02-23 2006-08-31 Medizinische Universität Graz Use of a compound with clusterin activity for the treatment of diseases associated with the deposition of abnormal proteins
WO2006096653A2 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US20080307537A1 (en) 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
WO2006113671A2 (en) 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Methylation markers for diagnosis and treatment of cancers
WO2007022248A2 (en) 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1937815B1 (en) 2005-09-13 2015-05-13 National Research Council of Canada Methods and compositions for modulating tumor cell activity
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CA2634146A1 (en) 2005-12-19 2007-06-28 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
WO2007071053A1 (en) 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
KR100679173B1 (ko) 2006-02-28 2007-02-06 주식회사 바이오인프라 위암 진단용 단백질 마커 및 이를 이용한 진단키트
NO347079B1 (no) 2006-03-23 2023-05-08 Bioarctic Neuroscience Ab Forbedrede protofibrilselektive antistoffer og anvendelse derav
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US8329399B2 (en) 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
WO2008085024A1 (en) 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
GB0703652D0 (en) 2007-02-26 2007-04-04 Univ Bradford Method for the allosteric modulation of beta1 integrin
WO2009006382A1 (en) 2007-07-02 2009-01-08 Purdue Research Foundation Detection of glycopeptides and glycoproteins for medical diagnostics
WO2009034562A2 (en) 2007-09-11 2009-03-19 Dublin City University A method of assessing lung squamous cell carcinoma status in an individual
US8617877B2 (en) 2007-11-02 2013-12-31 The Johns Hopkins University Cardiac stem cell and myocyte secreted paracrine factors
US7923253B2 (en) 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
EP2071336A1 (en) 2007-12-13 2009-06-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
US8575107B2 (en) 2008-01-22 2013-11-05 Compugen Ltd. Clusterin derived peptide
WO2009116860A1 (en) 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
KR101110758B1 (ko) 2008-06-02 2012-02-15 경북대학교 산학협력단 뇌졸중 표적용 펩티드 및 이의 용도
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010030980A2 (en) 2008-09-12 2010-03-18 University Of South Florida Akt and clusterin as biomarkers of chemotherapeutic responsiveness
WO2010118521A1 (en) 2009-04-17 2010-10-21 National Research Council Of Canada Peptide ligands for clusterin and uses thereof
PT2504363T (pt) * 2009-11-24 2019-08-02 Nat Res Council Canada Anticorpos anticlusterina e fragmentos de ligação ao antigénio e a sua utilização para reduzir o volume de um tumor
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Also Published As

Publication number Publication date
US9822170B2 (en) 2017-11-21
WO2013123588A1 (en) 2013-08-29
AU2013224591A1 (en) 2014-07-24
EA201491568A1 (ru) 2014-11-28
JP2015512877A (ja) 2015-04-30
AU2013224591A9 (en) 2015-07-23
US20150044220A1 (en) 2015-02-12
MX2014010164A (es) 2014-11-25
EP2817028A4 (en) 2015-11-04
CA2862739A1 (en) 2013-08-29
WO2013123588A9 (en) 2014-09-04
BR112014020756A2 (pt) 2017-07-04
EP2817028A1 (en) 2014-12-31
CN104159611A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
NZ626742A (en) Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
PH12016501384A1 (en) Human antibodies to pd-l1
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
NZ741324A (en) Anti-cd47 antibodies and methods of use
NZ631197A (en) Anti sez6 antibodies and methods of use
TR201812261T4 (tr) Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
NZ611785A (en) Anti-notch1 antibodies
JO3097B1 (ar) الأجسام المضادة c-Met
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
MX343227B (es) Anticuerpos anti-erbb3.
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MX2016004286A (es) Biomarcadores de cancer y usos de los mismos.
HK1213924A1 (zh) 用於治療癌症的抗kir和抗ctla-4抗體組合
UA117121C2 (uk) Біспецифічне антитіло до egfr/с-мет
MX2013004761A (es) Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
MX358728B (es) Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
MX338185B (es) Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
BR112015003757A2 (pt) anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase
MY186099A (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
UA100969C2 (uk) Антитіло, яке специфічно зв'язує людський альфа5бета1 (alpha5beta1)
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2018 BY FB RICE

Effective date: 20170215

LAPS Patent lapsed